Ganoderma, a fungal genus, is a
traditional medicine with immuno-modulating effects.
Asthma is an inflammatory disease of airways, and the main trigger of
asthma is allergic
inflammation. In this study, the effects of Ganoderma (an
anti-inflammatory agent) given via
oral administration (G/O) or
intraperitoneal injection (G/IP) on
asthma was evaluated. Forty BALB/c mice were divided into four groups, including the control, OVA-challenge, OVA-challenge + G/O, and OVA-challenge + G/IP. To determine AHR, the MCh challenge test was done. The levels of IL-1β, -4, -5, -6, -8, -10, -12, -13, -17, -25, -33, -38,
Cys-LT,
LTB4, and
hydroxyproline were measured. Finally, lung histopathology was evaluated to determine eosinophilic
inflammation, goblet cell
hyperplasia, and mucus hyper-secretion. Treatment with G/O and G/IP could significantly reduce the levels of IL-1β, -5, -6, -8, -17, -25, -33, and -38; the levels of
IL-4 and
IL-13 had no significant changes, but the levels of
IL-10 and
IL-12 were enhanced. The mice treated with G/O and G/IP showed decreased levels of
Cys-LT,
LTB4, peribronchial and perivascular
inflammation, but no significant changes were observed in AHR,
hydroxyproline level, goblet cell
hyperplasia, and mucus hyper-secretion. Ganoderma can be applied as an immunomodulatory and
anti-inflammatory agent for managing
asthma.